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Abstract 
Background: The precise immune responses mediated by HLA class I molecules such as HLA-B*27:05 and HLA-
B*57:01 that protect against HIV disease progression remain unclear. We studied a CRF01_AE clade HIV infected 
donor-recipient transmission pair in which the recipient expressed both HLA-B*27:05 and HLA-B*57:01.
Results: Within 4.5 years of diagnosis, the recipient had progressed to meet criteria for antiretroviral therapy initia-
tion. We employed ultra-deep sequencing of the full-length virus genome in both donor and recipient as an unbi-
ased approach by which to identify specific viral mutations selected in association with progression. Using a heat 
map method to highlight differences in the viral sequences between donor and recipient, we demonstrated that 
the majority of the recipient’s mutations outside of Env were within epitopes restricted by HLA-B*27:05 and HLA-
B*57:01, including the well-studied Gag epitopes. The donor, who also expressed HLA alleles associated with disease 
protection, HLA-A*32:01/B*13:02/B*14:01, showed selection of mutations in parallel with disease progression within 
epitopes restricted by these protective alleles.
Conclusions: These studies of full-length viral sequences in a transmission pair, both of whom expressed protective 
HLA alleles but nevertheless failed to control viremia, are consistent with previous reports pointing to the critical role 
of Gag-specific CD8+ T cell responses restricted by protective HLA molecules in maintaining immune control of HIV 
infection. The transmission of subtype CRF01_AE clade infection may have contributed to accelerated disease pro-
gression in this pair as a result of clade-specific sequence differences in immunodominant epitopes.
Keywords: HIV-1, HLA, CTL response, CRF01_AE Clade, Transmission pair, Ultra-deep sequencing
© 2015 Brener et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Human leukocyte antigen (HLA) class I genotype has been 
consistently linked to outcome of HIV infection [1–5]. 
Among infected Caucasians, HLA-B*57 and HLA-B*27 
are the best predictors of immune control [6, 7]. A better 
understanding of disease progression in subjects express-
ing protective HLA alleles such as these provides potentially 
valuable insights into the fundamental basis of HLA-medi-
ated immune control, for which many distinct mechanisms 
have been proposed [8]. One mechanism believed to be 
important in contributing to the HLA associations with 
characteristic disease outcomes is the targeting of specific 
cytotoxic T lymphocyte (CTL) epitopes [9–17]. The subtype 
of HIV infection may therefore impact on disease control, 
by affecting the availability of certain specific T cell epitopes 
[18–20]. It remains unclear specifically which epitopes are 
most likely to induce the most effective anti-HIV immune 
responses. These considerations are important both for 
understanding the mechanisms of HLA-mediated immune 
control of viral replication and because CTL may play a crit-
ical role in HIV cure strategies [21].
Most studies of immune control in HIV-infected subjects 
expressing protective HLA alleles such as HLA-B*57:01 
and B*27:05 have focused on Gag, and in particular the 
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dominant CD8+ T cell responses targeting epitopes within 
p24 Gag. We investigated the case of an HIV infected 
transmission pair in which the recipient expressed both 
HLA-B*27:05 and HLA-57:01. Despite expression of these 
protective HLA alleles, disease progression occurred over 
four years from aviremia (viral load <50 copies/ml plasma) 
to antiretroviral therapy (ART) initiation, following a 
decline in absolute CD4 count to <350 cells/mm3. This 
study pursues the hypothesis that the CD8+ T cell epitopes 
important for immune control are those in which escape 
is selected in association with, or prior to, disease progres-
sion. Conversely, if escape has not occurred in parallel with 
disease progression, this would imply responses that do not 
protect against progression. We ultra-deep sequenced full-
length HIV genomes using the Illumina MiSeq platform in 
both donor and recipient in order to define the mutations 
associated with disease progression.
Results
Progression in a UK transmission pair with CRF01_AE virus 
infection
We studied an adult Caucasian transmission pair 
from the UK. The male donor (HLA‐A*02:01/32:01 
B*13:02/14:01 C*06:02/08:02) is believed to have 
acquired HIV infection in Thailand, and subsequently to 
have infected the female recipient (HLA-A*02:01/02:01 
B*27:05/57:01 C*01:02/06:02) in the UK. Both partners 
were diagnosed more than 2 years later when the recipi-
ent was HIV-tested during pregnancy (referred to as 
‘time 0’).
Using maximum likelihood analysis and Rega HIV-1 
Subtyping Tool, we confirmed that the transmission 
pair was infected with CRF01_AE clade virus (Figure 1a 
and data not shown), the recombinant virus prevalent in 
Thailand [22, 23]. The close phylogenetic relationship of 
donor and recipient viruses suggests that these subjects 
are likely to be transmission partners (Figure 1b). As evi-
dence to support the direction of transmission suggested 
by the clinical history, we found that an HLA-B*14:01 
associated escape mutation, Gag-K302R (within the Gag-
DA9 epitope [24]) present in the HLA-B*14:01-positive 
donor’s autologous virus, was transmitted to the HLA-
B*14:01-negative recipient and subsequently reverted 
to wild-type in the recipient (Figure  2). In contrast, 
the HLA-B*27:05 and HLA-B*57:01-driven mutants 
observed in the recipient were not present in the donor.
a
b
Figure 1 Phylogenetic trees demonstrating subtype and genetic proximity of sequences from an HIV transmission pair. a Maximum likelihood 
phylogenetic tree of 92 6803 bp nucleotide sequences, including consensus sequences for clades A, B, C and CRF01_AE, donor sequences from 
8, 20 and 42 months post-diagnosis and recipient sequences from 20, 42 and 52 months post-diagnosis and 82 CRF01_AE Clade sequences from 
Thailand (Los Alamos HIV database, http://www.hiv.lanl.gov/). Donor and recipient sequences (circled) cluster with CRF01_AE clade sequences from 
Thailand, confirming that the Thai epidemic is the likely source of infection. The bootstrap value based on 1,000 bootstrap replicates for the donor-
recipient cluster is shown in italics. b The close relationship between donor and recipient sequences supports transmission between these two 
subjects. Bootstrap values >0.75 based on 1,000 bootstrap replicates are shown in italics. Scale bars show number of substitutions per site.
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The HLA-B*27:05/57:01-positive recipient progressed 
to an absolute CD4+ T cell count of <350 cells/mm3, 
meeting the criteria for initiation of ART within 4.5 years 
of diagnosis (Figure  3b). The donor also progressed to 
ART initiation over a similar time period from diagnosis 
(Figure 3a) despite expressing three HLA molecules that 
have also been associated with some degree of protection 
against disease progression, HLA-A*32:01, HLA-B*13:02 
and HLA-B*14:01 [6, 7, 25].
HLA‑B*27 and ‑B*57 Gag escape mutations in the recipient
We initially focused on the well-studied Gag epitopes 
restricted by HLA-B*27:05 and HLA-B*57:01, believed 
to play a central role in immune containment in subjects 
expressing these alleles [8, 26–28]. The presence in the 
AE clade consensus of the very residues that are selected 
in B or C clade infected subjects as escape mutants in 
two of the four HLA-27:05/B*57:01-restricted p24 Gag-
specific epitopes, ISPRTLNAW (Gag 147-155, ‘ISW9’) 
and KAFSPEVIPMF (Gag 162-172, ‘KF11’), prompted the 
question of whether well-defined HLA-B*27:05/57:01-
restricted epitopes are accessible in AE clade infection. 
Only six out of 20 HLA-B*27/B*57-restricted epitopes 
(HLA-B*57 Gag-TW10, Pol-IW9, Pol-KF9; HLA-B*27 
Gag-IK9, Gag-KK10, Pol-KY9) previously shown to drive 
the selection of escape mutants [24], share the same con-
sensus sequence in B and AE clades (Figure 4).
In the HLA-B*27:05/57:01-positive recipient, the earli-
est sample was available for sequencing at 20 months fol-
lowing diagnosis, by which time progression was already 
evident (Figure  3b). The T242N mutation within the 
B*57:01-restricted epitope TSTLQEQIGW (Gag 240–
249, ‘TW10’) had already reached fixation by this time-
point, being present in 100% of the intra-host population 
detected by ultra-deep sequencing (Figure 2). The other 
two HLA-B*57:01-restricted Gag epitopes, ISPRTLNAW 
(Gag 147–155, ‘ISW9’) and KAFSPEVIPMF (Gag 162–
172, ‘KF11’) in consensus CRF01_AE Clade HIV already 
carry polymorphisms A146P/I147L and A163G/S165N 
that are well-characterized escape mutants within the B 
clade versions of these epitopes (Figure 4) [29, 30].
To investigate which HIV-specific CD8+ T cell responses 
were detectable at the earliest timepoint available in the 
recipient (20 months post-diagnosis), we undertook IFN-γ 
SW9
Figure 2 Sequence changes within Gag epitopes restricted by HLA-B*14, B*27 and B*57 identified by ultra-deep sequencing of an HIV transmis-
sion pair aligned to CRF01_AE clade consensus (bold) and B clade consensus sequence (grey). The frequency of minor variant haplotypes at the 
HLA-B*57 Gag-ISW9, HLA-B*57 Gag-KF11, HLA-B*57 Gag-TW10, HLA-B*27 Gag-KK10, and HLA-B*14 Gag-DA9 epitopes above a cut-off of 1% are 
shown. Depth of coverage ranges from 560 to 240,000 reads. Position 146 (flanking HLA-B*57 Gag-ISW9), associated with selection of an HLA-
B*57/58:01-selected A146P processing mutation in B clade infection, is also shown. Minor variant frequencies are rounded off to the nearest 1%.
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elispot assays using a panel of 410 overlapping 18mer 
peptides spanning the HIV proteome [31], and identified 
responses to 6 of these 18mers (Figure 5a). The dominant 
Gag responses were to the HLA-B*27-restricted epitope 
KRWIILGLNK (Gag 263–272, ‘KK10’), and to the B*57:01-
restricted epitope TSTLQEQIGW. In addition, there was a 
subdominant Vpr response and a high frequency response 
to the HLA-B*27:05-restricted epitope in Integrase, KRK-
GGIGGY (Pol 901-909, ‘KY9’), a response that is typically 
co-dominant with HLA-B*27:05 Gag-KK10 [32]. Whereas 
the HLA-B*27:05-KK10 and HLA-B*57:01-TW10 epitopes 
had escaped by the first timepoint (20 months in the recipi-
ent), this was not the case for the other epitopes. HLA-
B*27:05 Pol-KY9 did not drive selection of escape even at 
52 months post-diagnosis. These data support the hypoth-
esis that the dominant Gag epitopes, including HLA-
B*27:05-KK10 and the HLA-B*57:01-TW10, are critical for 
maintaining immune control.
Although an IFN-γ ELISpot response to the TW10 
epitope was observed, no response to the autologous 
T242N variant was observed, and no CD8+ T cell 
responses were detectable in this subject to either the 
B clade or AE clade version of these ISW9 and KF11 
epitopes (Figure  5). At 20  months after diagnosis, the 
HLA-B*27-restricted epitope KRWIILGLNK (Gag 
263–272, ‘KK10’), believed to play an important role in 
HLA-B*27-mediated immune control of HIV [8, 26–28, 
33], also contained the escape mutation N271H in 100% 
of the recipient sequences (Figure 2), despite persistence 
of a substantial ex vivo T cell response to the wild type 
and N271H variant epitopes (Figure 5b, c). Thus, in the 
case of the HLA-B*27:05/57:01-positive recipient, disease 
progression was seen in association with mutations in all 
four HLA-B27:05/*57:01-restricted p24 Gag epitopes.
The majority of sequence changes selected in the recipient 
are escape polymorphisms in known epitopes
To investigate whether other sequence changes outside of 
the well-studied region of p24 Gag might also have con-
tributed to progression in the HLA-B*27:05/57:01-posi-
tive recipient, we next examined the ultra-deep sequence 
data of the full-length HIV genome. Heat maps were gen-
erated in order to visualize the proportion of amino acid 
variants at each position compared to a given baseline. 
We identified all sites of complete amino acid mismatch 
between the donor and recipient that reflect inter-
host evolution using the donor consensus sequence at 
8 months as the baseline for comparison to the recipient 
(Figure 6a). We also identified sites of amino acid diver-
sity in the recipient at 52  months, demonstrating intra-
host evolution, using the recipient consensus sequence 
at the same timepoint as the baseline for comparison 
(Figure  6b). The heat map analyses that were generated 
highlight the location of residues changing most rapidly 































Figure 3 Course of infection in an HIV transmission pair. a Longitudinal plasma HIV RNA viral load and CD4+ T cell counts for the donor over 
60 months of follow up. Grey shading represents the period during which the subject received antiretroviral therapy (ART) following decline of the 
CD4+ T cell count to <350cells/mm3 [58]. The horizontal dotted line represents the limit of detection (LOD) of the viral load assay (40 copies/ml). 
Arrows indicate the time of sampling for ultra-deep sequencing. b Longitudinal plasma HIV RNA viral load and CD4+ T cell counts for the recipient 
showing disease progression over 54 months of follow up. Grey shading represents the periods during which the subject received antiretroviral 
therapy (ART), initially as peri-partum prophylaxis and subsequently following decline of the CD4+ T cell count to 350cells/mm3 at 55 months 
post-diagnosis [58]. The horizontal dotted line represents the limit of detection (LOD) of the viral load assay (40 copies/ml). Arrows indicate the time 
of sampling for ultra-deep sequencing.
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in the recipient and which arose within CD8+ T cell 
epitopes (Figures 6, 7).
Using the donor consensus sequence at 8 months post-
diagnosis as the closest approximation of the transmit-
ted founder virus, we identified 16 residues across the 
full-length genome at which the residue in the donor 
(including minor variant residues) had been entirely 
replaced in the recipient by 52  months post-diagnosis. 
Excluding four residues within Env that are most likely to 
be susceptible to changes driven by neutralizing antibody 
Figure 4 Alignment of HLA-B*27:05 and HLA-B*57:01-restricted epitopes in an HIV-1 transmission pair, showing sequences derived from donor 
and recipient, compared to consensus sequences for B clade and CRF01_AE clade. Known escape mutations in B clade infection are indicated in 
bold.
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responses, eight of the remaining 12 were in or flanking 
known epitopes, in seven cases either restricted by HLA-
B*27:05 or HLA-B*57:01 (Figure  7). None of these sites 
are within epitopes restricted by HLA alleles expressed 
by the donor, indicating that these sequence changes are 
attributable to active selection in the recipient, rather 
than reversion of transmitted mutants selected in the 
donor.
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Figure 5 Quantification of CD8+ T cell responses to HLA-B*57 and HLA-B*27-restricted Gag epitopes in the recipient from an HIV transmission pair. 
a IFN-γ ELISpot responses at 20 months post-diagnosis in response to 410 18mer peptides spanning the B clade proteome. Responses to six 18mer 
peptides were detected. b IFN-γ ELISpot responses at 20 months post-diagnosis, showing maintenance of large responses to HLA-B*27 Gag-KK10 
(KRWIIGLNK) and the N271H variant of this epitope and moderate responses to the HLA-B*57 Gag-TW10 epitope (TSTLQEQIGW), regardless of 
sequence changes within the autologous virus, with no responses to KF11 (KAFSPEVIPMF) or ISW9 (ISPRTLNAW) and their variants above the cut-
off. Spot forming units (SFU) per million PBMC above a cut-off of 50 SFU/million are reported. Responses >2,000 SFU/million PBMC (OLP 36, KK10 
and KK10-N271H) could not be quantified precisely. c HLA-B*27:05-KK10 tetramer stains at 20 and 42 months post-diagnosis show maintenance 
of a large Gag-KK10-specific CD8+ T cell population. d HLA-B*57:01-Gag-KF11 tetramer stain at 42 months post-diagnosis shows no detectable 
Gag-KF11-specific CD8+ T cell population.
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Although these data from this single transmission pair 
do not definitively limit the most effective CD8+ T cell 
responses to this group of seven epitopes, these data are 
consistent with the hypothesis that the most effective 
responses are among this group. Of note, these do not 
include many of the well-studied HLA-B*27:05/57:01-
restricted epitopes that, like the Gag epitopes, 
ISPRTLNAW (Gag 147–155, ‘ISW9’) and KAFSPEVI-
PMF (Gag 162–172, ‘KF11’), are mutated in AE clade 
compared to B clade virus (Figure  4), and in this trans-
mission pair did not differ between donor and recipient 
at the timepoints compared.
To identify additional sites across the full-length 
genome in the recipient that were subject to turnover 
without having reached fixation yet, we sought sites at 
which amino acid diversity of at least 10% was present 
in the intra-host population at 52  months post diagno-
sis (Figure 6b, Additional file 1: Figure S1). This demon-
strated diversity at only 2.6% of all amino acid residues, of 
which the majority (1.1%) were in Env, a highly variable 
region of the genome where mutations are driven largely 
by neutralizing antibody responses. Of the remaining 
sites of diversity, 16% were within or flanking recognized 
HLA-B*27/-B*57 epitopes. In both the donor/recipient 
a b
c d
Figure 6 Comparison of inter- and intra-host diversity of HIV quasispecies in a transmission pair. a Heat map representation of inter-host amino 
acid diversity across the full-length HIV genome, comparing donor and recipient. For the baseline, we used the donor sequence at 8 months post-
diagnosis (which in this case represents the closest approximation of the founder virus); variation in the recipient at 52 months post-diagnosis is 
compared to this baseline. Each square represents a single codon, coloured to reflect the percentage of sequences in the recipient that differ from 
the consensus residue in the donor. b Heat map representation of intra-host amino acid diversity in the recipient at 52 months post-diagnosis. For 
the baseline, we used the recipient consensus sequence at 52 months post-diagnosis to which the intra-host recipient population at the same 
timepoint is compared. Each square represents a single codon coloured to reflect the percentage of minor variants in the recipient that differ from 
the consensus (‘baseline’) residue. c Percentage of true amino acid mismatches (excluding positions where the recipient’s sequence was repre-
sented as a minor variant in the donor) between donor and recipient sequences by gene. The proportion of mismatches at sites where there is a 
known or predicted association with the recipient’s HLA alleles is indicated. d Percentage of diverse amino acid sites (variability >10%) in the recipi-
ent intra-host population by gene. The proportion of diverse sites where there is a known or predicted association with the recipient’s HLA alleles is 
indicated.
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comparison (Figure  6a) and intra-host diversity plot 
(Figure  6b) the evolving sites in Gag were frequently 
within known or predicted CTL epitopes restricted by 
the recipient’s HLA alleles, whereas those outside of Gag, 
especially in Env or Nef, were rarely within known or 
predicted epitopes (Figure 6c, d).
Sequence changes in the donor reflect escape 
polymorphisms selected in known epitopes
Finally, we examined the sequences in the donor, who 
progressed despite possessing the protective HLA-
A*32:01, HLA-B*13:02 and HLA-B*14:01 alleles. Com-
pared to the full-length CRF01_AE clade consensus 
sequence, there are six epitopes at which HLA-associated 
mutations are present in the donor, two of which are in 
p24 Gag. These are within epitopes restricted by HLA-
B*13:02 (Gag 135–143, ‘VV9’) and B*14:01 (Gag 298–
306, ‘DA9’) respectively (Additional file  2: Figure S2). 
Thus, as in the recipient, progression to HIV disease in 
the donor was associated with mutations in critical p24 
Gag epitopes.
Discussion
This study capitalizes on longitudinal data from a well-
characterized transmission pair, for whom we were 
able to maximize the depth (ultra-deep approach) and 
breadth (full-length HIV genomes) of sequence resolu-
tion. This allowed us to quantify precisely the evolution 
of escape mutations, including minor variants, in the 
context of what would usually be regarded as a highly 
favorable combination of HLA alleles, HLA-B*27:05 and 
HLA-B*57:01. Since both these alleles occur at a very low 
frequency within the Thai population (approximately 0.2 
and 1.4% respectively [34]) finding this haplotype in the 
context of CRF01_AE clade infection is an ‘accident of 
nature’ which provides a unique opportunity to study the 
mechanisms of immune control.
There are conflicting data regarding the extent to which 
HLA-B*57 may be protective in Thai cohorts. Although 
a recent study in a particular Thai cohort, where 
the median CD4+ T cell count was only 86 T cells/
mm3,  reported that HLA-B*57:01 was protective [34], a 
parallel study of 116 transmission pairs found no benefit 
of HLA-B*57 [35]. The latter result fits with the picture 
we describe in our HLA-B*57-positive recipient, and is 
consistent with the abrogation of HLA-B*57-restricted 
Gag epitopes due to pre-existing polymorphisms 
in CRF01_AE clade virus that represent HLA-B*57 
escape mutations. This highlights the extent to which 
clade of infection may be an important determinant of 
Figure 7 Schematic representation of sites of complete amino acid mismatch between the donor and recipient full-length HIV sequences. The 
recipient consensus sequence at 52 months is aligned to the donor consensus sequence at 8 months (the latter being the closest representation 
of the transmitted HIV sequence). The sites shown in this figure are complete mismatches between donor and recipient identified in the heat map 
analysis (red squares, Figure 6a) The mismatched residue is indicated in bold. HLA-B*27:05, B*57:01 and C*01:02-restricted epitopes are shown in red, 
blue and green respectively. Mismatched residues that do not fall within a relevant HLA-Class I epitope are shown in yellow.
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immunological and clinical outcomes; even in an individ-
ual expressing a favourable combination of HLA alleles 
that are usually strongly linked to immune control, rapid 
progression may result in the context of infection with a 
viral sequence bearing pre-existing escape mutations.
Although HIV is recognised as a highly polymorphic 
virus, this study demonstrates that viral evolution is fre-
quently constrained to specific amino acid residues, with 
the success of the CD8+ T cell response dependent on 
these sites. In fact, significant variability (>10%) was 
evident within the intra-host population at only 2.6% of 
amino acid residues in the recipient. Ultra-deep sequenc-
ing demonstrated a high degree of conservation within 
key HLA-B*27:05 and HLA-B*57:01-restricted epitopes 
(Figure 2), with the exceptions being at pre-defined sites 
of escape mutation, most often corresponding to anchor 
residues. This points to selection pressure that is very 
specifically directed at these particular sites, consistent 
with previous reports showing that selective escape from 
CD8+ T cell responses follows constrained evolutionary 
pathways [36].
Consistent with previous reports [35, 37], in the 
recipient, we observed the robust selection of the Gag 
HLA-B*57-selected T242N mutation in the Gag-TW10 
epitope, that reaches fixation and is maintained in the 
host viral population. Within the Gag-KK10 epitope, 
strong selection pressure drives N271H selection almost 
to fixation. Subsequent reversion to the wildtype residue 
in a substantial proportion of the variants does, however, 
indicate more complexity in the adaption of the autolo-
gous virus at this site.
Explaining variation at certain sites is made more 
complicated by multiple influences on viral polymor-
phism. For example, Gag P146S is a common variant in 
CRF01_AE Clade infection (occurring in approximately 
9.5% of sequences), but this site is also subject to selec-
tion pressure from both HLA-B*13:02 and HLA-B*57:01-
mediated T cell responses [12, 18, 24]. Variation at this 
position in our study could therefore be attributed to 
selection pressure from either the donor or recipient 
CD8+ T cell response, or to a founder virus bearing a 
serine variant rather than the more common proline. An 
alternative explanation for sequence variation occurring 
over time in a transmission pair is that more than one 
transmission event has taken place; the introduction of 
a new founder virus could then alter the dominant qua-
sispecies. In this instance, re-infection appears unlikely 
on the basis of phylogeny demonstrating clear clustering 
of donor and recipient sequences respectively, but can-
not be excluded completely due to the limited number of 
samples analyzed over the time period of follow up.
It is striking that even by applying an unbiased 
approach to seeking sequence variability across the whole 
genome, the majority of polymorphisms identified in 
the recipient were within or flanking known epitopes, 
with HLA-B*27 and HLA-B*57-restricted epitopes being 
dominant, and Gag accounting for the greatest number 
of these. The observations made here, using the approach 
of this genome-wide search for polymorphisms, there-
fore corroborate previous data in studies that have used 
known CD8+ T cell epitopes or IFN-γ ELISpot assays as 
their starting point to identify sites of immune selection 
[30, 32, 37].
The unique nature of the circumstances described in 
this report mean that the findings are difficult to repli-
cate, and can be presented as a case study only. An addi-
tional limitation for this transmission pair was lack of 
information about the precise timing of infection, and 
absence of samples from timepoints closer to the time 
of transmission. Furthermore, a lack of data on the 
epitopes restricted in the context of this rare combina-
tion of HLA allele and clade of infection has limited our 
analysis of epitopes to those that have been described 
in the context of B clade infection. It is noteworthy, 
for example, that the B*27:05-KK10 variant selected 
in the clade AE-infected recipient was N271H that has 
been rarely observed in B clade infection. In this case, 
a strong N271H-specific CTL response was observed, 
which may appear counter-intuitive if N271H is 
selected as an escape mutant. However, it has been well 
described with respect to escape mutants that affect T 
cell receptor recognition, such as the more commonly 
observed L268M within KK10 [38–40], that a high fre-
quency response can be observed to a TCR-variant 
when it is recognised by a subset of CTL clones. Despite 
these caveats, this transmission pair provided a unique 
insight, gained by full-length ultra-deep sequencing 
data, supporting the association between the selection 
of polymorphisms to allow escape from HLA-B*27 and 
HLA-B*57-restricted epitopes, and loss of immunologi-
cal control.
Conclusions
The unique opportunity to study CRF01_AE Clade HIV 
infection longitudinally in the context of a transmis-
sion pair with protective HLA alleles, using ultra-deep 
sequencing and an unbiased approach to full-length 
sequence analysis, has shown the extent to which the 
polymorphisms associated with disease progression are 
constrained to very specific amino acid sites, frequently 
within Gag-restricted epitopes. The extent to which 
selection of escape mutations is robust and predictable is 
surprising given the overall plasticity of the HIV genome. 
This observation is encouraging for the development of T 
cell vaccines for which meeting the challenges presented 
by viral escape is a major consideration.
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Methods
Study subjects
This adult Caucasian transmission pair was recruited 
from the Thames Valley Cohort, UK, previously 
described [32]. A male donor, infected prior to 2007 sub-
sequently infected his female partner. Both subjects gave 
written informed consent for their participation. Eth-
ics approval was given by the Oxford Research Ethics 
Committee.
HLA typing
DNA extraction was performed from whole blood using 
PureGene reagents (Qiagen, UK). Four-digit high reso-
lution Sequence Based Typing of HLA-A, -B, and -C 
was performed from genomic DNA in the CLIA/ASHI 
accredited laboratory of William Hildebrand, PhD, 
(ABHI) at the University of Oklahoma Health Sciences 
Center using a locus specific PCR amplification strategy 
and a heterozygous DNA sequencing methodology for 
exon 2 and 3 of the class I PCR amplicon. Relevant ambi-
guities [41] were resolved by homozygous sequencing.
Viral load and CD4 testing
HIV viral load testing was performed using the Roche 
Amplicor version 1.5 assay (Roche, Switzerland). CD4+ 
T cell counts were determined by flow cytometry.
RNA extractions and viral amplification using PCR
RNA extractions were performed using the Qiamp Viral 
RNA Mini Kit (Qiagen, UK). 1 ml aliquots of plasma were 
centrifuged for 1 h at 21,000 rpm and 860 μl of superna-
tant removed before proceeding according to the manu-
facturer’s instructions. Samples with a viral load below 
3,000 copies/ml were concentrated by processing 3 ali-
quots of plasma on the same Qiamp column. PCR ampli-
fication of the full HIV genome was performed in four 
fragments using Superscript III One-Step RT PCR Kit 
with Platinum Taq High Fidelity enzyme (Invitrogen, UK) 
as previously described [42].
Ultra‑deep sequencing and de novo assembly 
of consensus sequences
Ultra-deep sequencing of the HIV genome (complete 
amino acid coding region and partial long terminal 
repeats) was performed as previously described [43]. 
Amplicons were pooled for Illumina library prepara-
tion, including a unique bar code for each sample, and 
sequenced using MiSeq 250 bp paired-end technology in 
a pool of 9, 15 and 27 libraries, respectively [44]. Qual-
ity control (removing reads of <50  bp and trimming 
low-quality bases from the 3′-end of the reads until the 
median quality of the read was 30) was carried out using 
QUASR (http://www.sourceforge.net/projects/quasr/). A 
de novo assembly was constructed using SPAdes version 
2.4.0 [45]. Resulting contiguous sequences were aligned 
with the sequence of the HIV CRF01_AE reference strain 
CM240 (accession number U54771), and a consensus 
sequence was generated using Abacas version 1.3.1 and 
MUMmer version 3.2 [46].
Minor variant analysis
The raw reads were assembled by Vicuna [47] and V-
FAT [48] to form a single genome, which represents the 
majority base at each nucleotide position (the consensus 
assembly). The reads were then aligned to the consensus 
assembly using Mosaik [49]. V-Phaser2 [50] was used 
in order to call variants. This program uses both quality 
scores as well as covariation between variants (observa-
tion of two variants on the same read) to separate real 
variants from sequencing artifacts. We applied a modi-
fied strand bias cut-off to the variant calls. We required 
the odds-ratio of the appearance of a mutation between 
the two directions to be larger than 3.
Heat map analysis
Heat maps of intra-host diversity were created using 
Vprofiler [51] as well as custom programs written in 
Perl and R. We carried out diversity heat map analysis 
on the recipient at 52  months post-diagnosis (the earli-
est timepoint at which full-length sequencing data were 
available) and on the donor at 8  months post-diagnosis 
(representing the timepoint closest to the time of trans-
mission). This method provides colour plots that repre-
sent the extent of variability across the HIV proteome, 
either comparing sequences between two individuals (in 
this case, donor and recipient), or representing diver-
sity within one individual at a given time point (in this 
case, providing a snapshot of within-host diversity in the 
recipient at time 52 months).
Determination of haplotypes
Haplotypes in the epitope regions were determined 
using Vprofiler [51] by selecting reads that span the 
epitope region and which contain only accepted variants. 
This analysis is limited to positions that are within the 
sequence read length of 250 bp.
Epitopes known or predicted to be restricted by expressed 
HLA‑alleles
We focused on HLA-B restricted epitopes, since the 
HLA-B alleles are most strongly linked to HIV disease 
outcome in HIV infection [52] and there are no sig-
nificant HLA associations with disease control for the 
HLA-A and HLA-C alleles expressed by this transmis-
sion pair. Known epitopes were identified from The Los 
Alamos Immunology Database CTL Epitopes A-list [53]. 
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Predicted epitopes were identified from described HLA 
footprints [24] and the HLArestrictor tool [54].
IFN‑γ ELISpot assays
We tested cryopreserved peripheral blood mononu-
clear cells (PBMC) from the recipient collected at 20 
and 42 months post-diagnosis against HLA-B*27:05 and 
HLA-B*57-restricted Gag epitope peptides including 
CRF01_AE clade-specific peptide variants, to screen for 
IFN-γ ELISpot responses as previously described [31]. 
IFN-γ ELISpot responses to 410 18mer overlapping pep-
tides spanning the B clade proteome were also tested, as 
previously described [31].
Phylogenetic analysis
Maximum likelihood phylogenetic trees using the gen-
eral time reversible model of nucleotide substitution, as 
determined by jModelTest version 0.1.1 [55], were con-
structed from near-full genome (6,803  bp) data with 
1,000 bootstrap replicates using Mega 6.06 software and 
viewed using FigTree v1.4.0 software. Clade consensus 
sequences were generated using full-length sequences 
and the Simple Consensus Maker tool available from the 
Los Alamos HIV database (http://www.hiv.lanl.gov/). 
Eighty-two full-length AE clade reference sequences 
from Thailand collected from the same database were 
included as reference sequences. All reference sequences 
were based on data collected after 2004. Sequence sub-
types were confirmed using REGA HIV-1 Subtyping Tool 
version 3.0 [56].
Peptide‑MHC tetramer staining and flow cytometry
Peptide-MHC tetramers were generated as previously 
described [57]. Cryopreserved PBMC (1 million per 
stain) from the recipient collected at 20 and 42 months 
post-diagnosis were stained with PE-conjugated HLA-
B*27:05-KK10 and HLA-B*57:01-KF11 peptide-MHC 
tetramers, anti-CD3 Pacific Orange (Invitrogen, UK), 
anti-CD4 AlexaFlour700 (BD Biosciences, UK) and ant-
CD8 V450 (BD Biosciences, UK) antibodies and near-IR 
Live/Dead marker (Invitrogen, UK). Samples were ana-
lyzed using an LSRII flow cytometer (BD, UK) collect-
ing a minimum of 500,000 events and gating on singlets, 
lymphocytes, live cells and CD3 + cells. Data were ana-
lyzed using FlowJo version 10.0.7.
Sequence accession numbers
The Illumina MiSeq sequencing data obtained in 
this study are available from the EMBL/GenBank/
DDBJ Sequence Read Archive under accession num-
bers: ERS250039, ERS250040, ERS250041, ERS250042, 
ERS394610 and ERS394611. Consensus sequences have 
been deposited in GenBank under the accession num-
bers: KP873161-KP873166.
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Additional file 1: Figure S1. Sites of amino acid diversity in the recipi-
ent from an HIV transmission pair at 52 months post-diagnosis. Diverse 
sites are defined as amino acid positions with diversity of ≥10% in the 
intra-host population. Sites that fall within or flanking known or predicted 
HLA-B*27:05, B*57:01 and C*01:02-restricted epitopes are shown in red, 
blue and green respectively. Duplicated sites, present due to overlap in 
the Gag/Pol and Vif/Vpr reading frames, are shown in grey.
Additional file 2: Figure S2. Sites of HLA-associated footprints in the 
donor from an HIV transmission pair at 8 months post-diagnosis aligned 
to B and CRF01_AE clade consensus sequence. Epitopes restricted by the 
favourable alleles expressed by the donor, A*3201, B*1302 and B*1401, 
are shown.
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